Inclusion Criteria:

1. Healthy volunteers aged between 18 and 55 years old (including 18 and 55 years old),
regardless of gender.

2. For male volunteers, the body weight should be ≥ 50.0 kg, and for female volunteers,
the body weight should be ≥ 45.0 kg. The body mass index (BMI) = body weight (kg) /
height² (m²), and it should be within the range of 19.0 to 28.0 kg/m². Women of
childbearing potential (WOCBP) or the female partners of male subjects should be
willing to have no plans for childbearing from 2 weeks before the screening until 3
months after the last administration of the investigational medicinal product, and
voluntarily adopt effective contraceptive measures (including one or more
non-pharmacological contraceptive measures), and have no plans for sperm donation or
egg donation.

3. No history of major diseases, and the results of physical examination, vital signs,
12-lead electrocardiogram, chest X-ray examination and laboratory tests during the
screening period are normal, or although slightly beyond the normal reference value
range, they are judged by the investigator to have no clinical significance.

4. The subject should be able to maintain good communication with the investigator,
comply with various requirements of the clinical trial, and voluntarily sign the
informed consent form.

Exclusion Criteria:

1. Diseases with abnormal clinical manifestations that occurred before screening or are
currently occurring and need to be excluded, including but not limited to those in
the nervous/mental system, respiratory system, cardiovascular and cerebrovascular
system, digestive system (any history of gastrointestinal diseases that affect drug
absorption), hematological and lymphatic system, urinary system, endocrine system,
and immune system.

2. Acute diseases that occurred from the screening stage to before the administration
of the investigational medicinal product and are judged by the investigator to
possibly affect the research results.

3. Subjects who cannot tolerate intravenous puncture or those with a history of syncope
judged by the investigator to be of clinical significance.

4. Subjects with difficulty in swallowing.

5. Subjects who are judged by the investigator to possibly or definitely have an
allergic reaction to the investigational drug, remdesivir (including similar drugs),
or any of its excipients; or subjects with an allergic constitution judged by the
investigator to be of clinical significance (a history of severe allergies to
multiple drugs and foods) or a history of allergic diseases.

6. Subjects who have undergone surgery before screening and are judged by the
investigator to possibly affect the absorption, distribution, metabolism, and
excretion of the drug, or subjects with severe surgical sequelae, or subjects who
plan to undergo surgery during the study period.

7. Subjects who donated blood or had massive blood loss (≥ 400 mL), donated ≥ 2 units
of component blood, or received a blood transfusion within 3 months before the first
administration of the trial, or those who plan to donate blood during the trial.

8. Subjects who received any investigational drug in a clinical study or participated
in any interventional clinical study within 3 months before the first administration
of the trial.

9. Subjects who smoked an average of more than 5 cigarettes per day within 3 months
before the first administration of the trial, or those who cannot stop using any
tobacco products during the trial.

10. Subjects who consumed an average of more than 14 units of alcohol per week within 3
months before the first administration of the trial (1 unit of alcohol ≈ 360 mL of
beer or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine), or those
who cannot stop using any alcohol-containing products during the trial, or those
with a positive alcohol breath test before the administration of the trial.

11. Subjects who consumed an excessive amount of tea, coffee, and/or caffeine-containing
beverages on average per day (more than 8 cups on average, 1 cup ≈ 250 mL) within 3
months before the first administration of the trial, or those who cannot stop
consuming tea, coffee, and/or caffeine-containing beverages during the trial.

12. Subjects who used any prescription drugs, over-the-counter drugs, traditional
Chinese patent medicines, Chinese herbal medicines, vitamins, or health foods within
28 days before screening or within 5 drug half-lives (whichever is longer).

13. Female subjects who are pregnant or breastfeeding, or those with a positive
blood/urine pregnancy test (only for WOCBP) at any time before the first
administration.

14. Positive results or results exceeding the upper limit of the reference range for the
four hemodialysis tests: hepatitis B surface antigen (HBsAg), quantitative hepatitis
C (HCV) antibody, quantitative human immunodeficiency virus (HIV) antibody, or
treponema pallidum antibody.

15. Subjects with a positive urine drug screening (morphine, tetrahydrocannabinolic
acid, methamphetamine, methylenedioxymethamphetamine, ketamine) or those with a
history of drug abuse or drug use within the past 5 years before the trial.

16. Subjects who consumed or drank pitaya, mango, pomelo, carambola, or foods or
beverages prepared from them, or foods or beverages containing xanthine, caffeine,
or alcohol (including chocolate, tea, coffee, cola, cocoa, etc.), or other special
diets that affect the absorption, distribution, metabolism, and excretion of the
drug within 72 hours before the first administration.

17. Subjects with special dietary requirements, lactose intolerance, or those who cannot
accept the unified diet.

18. Subjects who, according to the investigator's judgment, are not suitable to
participate in this trial.